Comparative Pharmacology
Head-to-head clinical analysis: CISPLATIN versus EVOMELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CISPLATIN versus EVOMELA.
CISPLATIN vs EVOMELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Platinum-based alkylating-like agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
50-100 mg/m² IV every 3-4 weeks; or 20 mg/m² IV daily for 5 days every 3-4 weeks.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
None Documented
None Documented
The terminal elimination half-life is 20-30 hours (range 10-40 hours) in patients with normal renal function. This prolonged half-life is due to slow release of platinum from tissue binding and is clinically relevant for cumulative nephrotoxicity and ototoxicity.
Clinical Note
moderateCisplatin + Digoxin
"Cisplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCisplatin + Digitoxin
"Cisplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCisplatin + Deslanoside
"Cisplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCisplatin + Acetyldigitoxin
"Cisplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
Renal excretion accounts for 70-90% of cisplatin elimination, with approximately 20-50% excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Category D/X
Category C
Alkylating Agent
Alkylating Agent